Opportunities and challenges of implementing Pharmacogenomics in cancer drug development

Abstract

Cancer drug development is a time and resources consuming process. Around 90% of drugs entering clinical trials fail due to lack of efficacy and/or safety issues, more often after conspicuous research and economic efforts. Part of the discarded drugs might be beneficial only in a subgroup of the study patients, and some adverse events might be prevented by identifying those patients more vulnerable to toxicities. The implementation of pharmacogenomic biomarkers allows the categorization of patients, to predict efficacy and toxicity and to optimize the drug development process. Around seventy FDA approved drugs currently present one or more genetic biomarker to keep in consideration, and with the progress of Precision Medicine tailoring therapies on individuals’ genomic landscape promises to become a new standard of cancer care. In the current article we review the role of pharmacogenomics in cancer drug development, underlying the advantages and challenges of their implementation.

Keywords

Pharmacogenomics / cancer drug development / precision medicine / clinical trials

References

[1] Elledge RM.Oestrogen receptors and breast cancer..BMJ1997;314:1843-4

[2] Park JW,Kelloff GJ,Chabner BA.Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development..Clin Cancer Res2004;10:3885-96

[3] Marcuello E,Menoyo A,Gómez-Pardo M.UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer..Br J Cancer2004;91:678-82 PMCID:PMC2364770

[4] US FDA. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm. [Last accessed on 27 Feb 2019]

[5] Pharmacogenetics FDA. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. [Last accessed on 27 Feb 2019]

[6] Thomas F.The anticancer drug development pipeline of the pharmaceutical (P) and biotech (B) industries..J Clin Oncol2009;27:

[7] Wheeler HE,Dolan ME,Ratain MJ.Cancer pharmacogenomics: strategies and challenges..Nat Rev Genet2013;14:23-34 PMCID:PMC3668552

[8] DiMasi JA,Hansen RW.Innovation in the pharmaceutical industry: new estimates of R&D costs..J Health Econ2016;47:20-33

[9] Hwang TJ,Lauffenburger JC,Franklin JM.Failure of investigational drugs in late-stage clinical development and publication of trial results..JAMA Intern Med2016;176:1826-33

[10] Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program. Available from: https://endpts.com/hammered-by-a-series-of-setbacks-newlink-axes-staff-again-and-circles-its-wagons-around-ido/. [Last accessed on 27 Feb 2019]

[11] FDA22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results..US Food Drug Adm2017;1-43

[12] Cook D,Alexander R,Morgan P.Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework..Nat Rev Drug Discov2014;13:419-31

[13] Morgan P,Lennard S,Barrett JC.Impact of a five-dimensional framework on R&D productivity at AstraZeneca..Nat Rev Drug Discov2018;17:167-81

[14] Motulsky AG.Drug reactions, enzymes, and biochemical genetics..J Am Med Assoc1957;165:835

[15] Yates CR,Loennechen T,Tai HL.Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance..Ann Intern Med1997;126:608-14

[16] Relling MV,Sandborn WJ,Pui CH.Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing..Clin Pharmacol Ther2011;89:387-91 PMCID:PMC3098761

[17] Innocenti F,Iyer L,Das S.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan..J Clin Oncol2004;22:1382-8

[18] Wei X,McMurrough J,Fernandez-Salguero P.Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity..J Clin Invest1996;98:610-5 PMCID:PMC507468

[19] Henricks LM,de Man FM,Frederix GWJ.DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis..Lancet Oncol2018;19:1459-67

[20] Goetz MP,Reid JM,Tan AD.UGT1A1 genotype-guided phase i study of irinotecan, oxaliplatin, and capecitabine..Invest New Drugs2013;31:1559-67 PMCID:PMC3880122

[21] Dean L.Pratt V,Rubinstein W,Kattman B.Irinotecan therapy and UGT1A1 genotype..SourceMedical Genetics Summaries [Internet].2012;Bethesda (MD)National Center for Biotechnology Information (US)

[22] Raida M,Häusler P,Van Gennip AH.Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5’-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls..Clin cancer Res2001;7:2832-9

[23] Ciardiello F,Casali PG,Douillard JY.Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)..Ann Oncol2014;25:1673-8

[24] Woodcock J.Master protocols to study multiple therapies, multiple diseases, or both..N Engl J Med2017;377:62-70

[25] Le Tourneau C,Gonçalves A,Dubot C.Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial..Lancet Oncol2015;16:1324-34

[26] Krop IE.Results from molecular analysis for therapy choice (MATCH) arm I: taselisib for PIK3CA-mutated tumors..J Clin Oncol2018;36:101

[27] Jhaveri KL.Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MAT)..J Clin Oncol2018;36:100

[28] Drilon A,Kummar S,Lassen UN.Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children..N Engl J Med2018;378:731-9

[29] Le DT,Wang H,Kemberling H.PD-1 blockade in tumors with mismatch-repair deficiency..N Engl J Med2015;372:2509-20

[30] O’Donnell PH.Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?.Clin Cancer Res2012;18:2809-16 PMCID:PMC3354016

[31] Lièvre A,Le Corre D,Landi B.KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer..Cancer Res2006;66:3992-5

[32] Storer BE.An evaluation of phase I clinical trial designs in the continuous dose-response setting..Stat Med2001;20:2399-408

[33] Rogatko A,Jonas W,Khuri FR.Translation of innovative designs into phase I trials..J Clin Oncol2007;25:4982-6

[34] Patnaik A,Rasco D,Elassaiss-Schaap J.Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors..Clin Cancer Res2015;21:4286-93

[35] Lindauer A,Mehta K,de Greef R.Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab..CPT Pharmacometrics Syst Pharmacol2017;6:11-20 PMCID:PMC5270293

[36] Connell CM.Activating HER2 mutations as emerging targets in multiple solid cancers..ESMO Open2017;2:e000279 PMCID:PMC5708307

[37] Guo B.Bayesian phase I/II biomarker-based dose finding for precision medicine with molecularly targeted agents..J Am Stat Assoc2017;112:508-20

[38] El-Maraghi RH.Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III..J Clin Oncol2008;26:1346-54

[39] Mandrekar SJ.Randomized phase II trials: time for a new era in clinical trial design..J Thorac Oncol2010;5:932-4 PMCID:PMC2941394

[40] Neel DS.Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma..NPJ Precis Oncol2017;1:3

[41] Remon J,Jovelet C,Lawson A.Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA..Ann Oncol2017;28:784-90

[42] Siravegna G,Buscarino M,Cassingena A.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients..Nat Med2015;21:795-801 PMCID:PMC4868598

[43] Goodall J,Yuan W,Porta N.Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition..Cancer Discov2017;7:1006-17 PMCID:PMC6143169

[44] Esposito A,Locatelli M,Curigliano G.Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies..Pharmacol Ther2016;157:120-4

[45] Pon JR.Driver and passenger mutations in cancer..Annu Rev Pathol Mech Dis2015;10:25-50

[46] Mateo J,Dienstmann R,Gonzalez-Perez A.A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)..Ann Oncol2018;29:1895-902 PMCID:PMC6158764

[47] Ellis L.The elusive search for biomarkers of anti-VEGF activity..Mol Diagnostics Cancer Ther Dev2007;13:PL06-01

[48] Patel SP.PD-L1 expression as a predictive biomarker in cancer immunotherapy..Mol Cancer Ther2015;14:847-56

[49] Singh RR,Routbort MJ,Medeiros LJ.Implementation of next generation sequencing in clinical molecular diagnostic laboratories: advantages, challenges and potential..Expert Rev Precis Med Drug Dev2016;1:109-20

[50] Pennell NA.Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model..J Clin Oncol2018;36:9031

[51] André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase 3 SOLAR-1 trial. Available from: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Alpelisib-ALP-fulvestrant-FUL-for-advanced-breast-cancer-ABC-results-of-the-Phase-3-SOLAR-1-trial. [Last accessed on 27 Feb 2019]